Clinical trial · Observational
Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy
Multicentre Observational Study Evaluating the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy, in Real Life Setting.
NCT04775446CI-TRIAL-00056332MESOIMMUNEcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of this multicentre descriptive analysis is to describe the clinical and biological characteristics of patients who have received Programmed cell death 1 (anti-PD1) / (PDL1) Programmed death-ligand 1 (PDL1) immunotherapy outside of a clinical trial in terms of efficacy and safety.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Pleural Mesothelioma | Pleural Malignant Mesothelioma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Data collection | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with malignant pleural mesothelioma treated with Nivolumab.
- description
- Patients with malignant pleural mesothelioma treated with Nivolumab.
- interventionNames
- Other: Data collection
Primary outcomes (1)
- measure
- Disease control
- timeFrame
- 12 weeks
- description
- Disease control rate at 12 weeks
Secondary outcomes (10)
- measure
- Survival with anti-PD1/PDL1 immunotherapy
- timeFrame
- 12 weeks
- description
- Overall survival from treatment with anti-PD1/PDL1 immunotherapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient over 18 years of age, * Diagnosis of malignant pleural mesothelioma affirmed by the anatomo-pathological analysis report of a histological sample of the tumour (re-read by MESOPATH). * Patient who has received at least one injection of anti-PD1 or anti-PDL1 antibodies Exclusion Criteria: * Explicit refusal by the patient to collect data
References
Publications (0)
Data not yet available
No reference posted for this study.